학술논문
6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Document Type
Abstract
Author
Source
In Immuno-Oncology and Technology December 2022 16 Supplement 1
Subject
Language
ISSN
2590-0188